Should I Buy NBY? NBY 2026 Analysis

Should You Buy NovaBay Pharmaceuticals Inc (NBY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

2.000

1 Day change

-15.61%

52 Week Range

19.950

Analysis Updated At

2026/01/26

NovaBay Pharmaceuticals Inc (NBY) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is experiencing significant negative momentum, poor financial performance, and lacks positive catalysts or strong trading signals. The recent stock sale agreement has caused a sharp decline in price, and there are no indications of recovery in the short term.

Technical Analysis

The stock is in a strong downtrend with a -14.05% regular market change and additional losses in pre-market (-3.47%) and post-market (-1.91%). The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 30.887, but nearing oversold territory. Moving averages are converging, providing no clear direction. Key support levels (S1: 5.962, S2: 2.348) are far below the current price of 4.62, suggesting further downside risk.

Options Data

Positive Catalysts

NULL identified.

Neutral/Negative Catalysts

The announcement of a $100 million stock sale agreement with Virtu Americas caused a 54% drop in stock price, indicating significant dilution concerns. Financial performance is weak, with declining net income (-41.68% YoY) and EPS (-88.54% YoY).

Financial Performance

In Q3 2025, revenue remained flat at $521,000 (0.00% YoY). Net income dropped significantly to -$1,293,000 (-41.68% YoY), and EPS fell to -0.22 (-88.54% YoY). Gross margin improved slightly to 8.06% but remains low overall. The company is struggling with profitability and growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

Analyst Rating

Wall Street analysts forecast NBY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBY is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold